Whitbread profit fuelled by Costa and Premier December 14, 2010 Britain’s biggest hotel and coffee shop operator Whitbread said it expected strong profit growth in its current financial year benefiting from increased sales at its Premier Inn and Costa Coffee chains. Whitbread, which also owns the Beefeater and Brewers Fayre restaurant chains, said sales at Premier Inn hotels open for more than a year grew [...]
Whitbread profit fuelled by Costa and Premier December 14, 2010 Britain’s biggest hotel and coffee shop operator Whitbread said it expected strong profit growth in its current financial year benefiting from increased sales at its Premier Inn and Costa Coffee chains. Whitbread, which also owns the Beefeater and Brewers Fayre restaurant chains, said sales at Premier Inn hotels open for more than a year grew [...]
Sentance: Act now on rates or risk sharp hike in future February 1, 2011 Interest rates must be steadily increased now to avoid a sudden and heavier rise down the line that would “jolt” the recovery, Bank of England monetary policy committee member Andrew Sentance told City A.M. in an exclusive interview. If the inflation “genie” comes out of the bottle, he said, the UK would face a “hard [...]
What the other papers say this morning January 23, 2011 FINANCIAL TIMES AUDITORS SEEK TO EASE FEARS The four biggest auditors have denied that their dominance of the market for large companies had created a systemic risk akin to that posed by the leading banks. Deloitte, Ernst & Young, KPMG and PwC have told the European Commission that they are willing to help draw up [...]
AstraZeneca counts cost of risky drug December 21, 2010 DRUGS company AstraZeneca has binned its experimental infant lung disease drug following objections from US regulators, costing the firm upwards of £286m. The company said yesterday its motavizumab drug would be discontinued, after Food and Drug Administration (FDA) advisers asked for more information on trials in June. The costs are linked to intellectual property and [...]
AstraZeneca counts cost of risky drug December 21, 2010 DRUGS company AstraZeneca has binned its experimental infant lung disease drug following objections from US regulators, costing the firm upwards of £286m. The company said yesterday its motavizumab drug would be discontinued, after Food and Drug Administration (FDA) advisers asked for more information on trials in June. The costs are linked to intellectual property and [...]
Euro air traffic down 15.6pc June 16, 2010 European passenger traffic fell by 15.6 per cent in April after taking a hit from the volcano disruptions. The numbers mark a drop from the 3.6 per cent rise reported by the industry in the first quarter. Figures from aviation body International Air Transport Association (IATA) showed that international passenger traffic was also adversely impacted [...]
FTSE 100 bounce back led by banks January 11, 2011 The FTSE 100 lifted in early trading today as banking stocks led the way. The recovery came after a poor session yesterday with the euro zone debt crisis casting a shadow over European markets. Citigroup upgraded HSBC to “buy” from “hold”, fuelling more confidence in the banking sector. Barclays also climbed as the London Stock [...]
FTSE 100 bounce back led by banks January 11, 2011 The FTSE 100 lifted in early trading today as banking stocks led the way. The recovery came after a poor session yesterday with the euro zone debt crisis casting a shadow over European markets. Citigroup upgraded HSBC to “buy” from “hold”, fuelling more confidence in the banking sector. Barclays also climbed as the London Stock [...]
UK service sector growth slows in November December 3, 2010 GROWTH in UK service sector activity slipped back slightly in November, suggesting a slowdown in overall fourth-quarter economic output and no change to monetary policy anytime soon. The headline business activity index in the Markit/CIPS PMI index eased to 53.0 in November from October’s four-month high of 53.2 and bang in line with the forecast, [...]